On September 28, 2026, Bill Wenqing Liang bought 25,100 H-shares of CF PHARMTECH on the SEHK open market at an average of HKD 7.2916 per share, involving about HKD 183,019, an on-exchange active trade representing a direct secondary-market dealing. The purchase was made pursuant to an acting-in-concert agreement with Dr. LI LI BOVET.
Prior to the acquisition, Bill Wenqing Liang's long position in CF PHARMTECH was 60.67 million shares, representing 18.73%; following the acquisition, the holding changed to 60.70 million shares, with the long position ratio rising to 18.74%.
This involves related parties: Dr. LI LI BOVET, as per the acting-in-concert agreement.